LADA, or latent autoimmune diabetes in adults, is a form of autoimmune diabetes that develops slowly in adulthood, typically after age 35. Like type 1 diabetes, the immune system attacks the insulin-producing cells in the pancreas. But unlike type 1, this destruction happens gradually over months to years, which is why LADA is often called “type 1.5 diabetes.” Because it appears later in life and progresses slowly, an estimated 5 to 10% of adults diagnosed with type 2 diabetes actually have LADA.
How LADA Differs From Type 1 and Type 2
LADA sits in a gray zone between type 1 and type 2 diabetes, sharing features of both. In type 1, the immune system rapidly destroys beta cells (the cells in the pancreas that make insulin), often within weeks or months. In LADA, that same autoimmune attack is happening, but the destruction is far slower. The immune cells involved are different too: LADA is driven primarily by a type of immune cell called a macrophage, while classic type 1 involves a more aggressive immune cell that kills beta cells faster.
This slower immune process means people with LADA still produce some insulin at diagnosis. Their C-peptide levels, a blood marker that reflects how much insulin the pancreas is making, tend to be low but detectable. In type 1, C-peptide is usually undetectable. In type 2, it’s normal or even high because the pancreas is still working, the body just isn’t responding well to insulin. One case study of a LADA patient found a C-peptide of 0.34 ng/mL, well below the normal range of 0.8 to 3.0 ng/mL but not completely absent.
Type 2 diabetes is driven by insulin resistance, often linked to excess weight. LADA patients tend to be leaner and don’t have the same degree of insulin resistance. They may look like type 2 patients on the surface, but the underlying mechanism is fundamentally different: their pancreas is under autoimmune attack, not struggling against resistance.
Why It Gets Misdiagnosed So Often
The biggest challenge with LADA is that it looks like type 2 diabetes at first. An adult in their 40s shows up with elevated blood sugar, and the default assumption is type 2. Standard oral medications may even work initially because the pancreas is still producing some insulin. It’s only when blood sugar control starts slipping despite medication that the picture becomes clearer.
Certain red flags suggest LADA rather than type 2. Clinicians at Duke Health recommend a screening approach based on five characteristics:
- Age of onset under 50
- Acute symptoms like excessive thirst, frequent urination, or unexplained weight loss
- BMI under 25 (a normal or lean body weight)
- Personal history of autoimmune disease
- Family history of autoimmune disease
If you have at least two of these features, antibody testing is warranted. Another important signal: not responding well to standard oral diabetes medications after lifestyle and compliance issues have been ruled out.
How LADA Is Diagnosed
The definitive test for LADA is a blood test for autoantibodies, proteins that indicate the immune system is targeting the pancreas. The most important one is called GAD65 (glutamic acid decarboxylase antibody). A positive GAD65 test in an adult who was initially thought to have type 2 diabetes is the hallmark of LADA. When two different autoantibodies come back positive, the likelihood of rapid insulin dependence and a clinical profile closer to type 1 increases significantly.
C-peptide testing adds another piece of the puzzle. A low C-peptide in someone with positive autoantibodies confirms that beta cells are already declining. These tests are practical and inexpensive, yet they’re not part of routine diabetes screening for most adults, which is why misdiagnosis is so common.
The Genetic Connection
LADA has its own genetic fingerprint. It shares some genetic risk factors with type 1 diabetes but not all of them. A specific immune system gene called HLA-DR3 is associated with LADA, while HLA-DR4, which is strongly linked to classic type 1, is not. Research across populations in Finland, Italy, India, and Latvia has identified a gene variant called MICA 5.1 that shows up consistently in LADA patients. These genetic markers help explain why LADA behaves differently from type 1, even though both are autoimmune conditions.
How Quickly LADA Progresses
Most people with LADA will need insulin within about three years of diagnosis. That timeline varies. Some people maintain partial beta cell function for several years, while others progress more quickly, particularly those with high levels of autoantibodies. The trajectory is always toward insulin dependence, though, because the autoimmune process doesn’t stop on its own. It just moves more slowly than in type 1.
During the early phase, when the pancreas is still producing some insulin, blood sugar may be manageable with diet, exercise, and certain medications. But this window closes as beta cells continue to decline.
Why the Right Treatment Matters Early
One of the most consequential mistakes in LADA management is treating it exactly like type 2 diabetes, specifically with a class of drugs called sulfonylureas. These medications work by forcing the pancreas to produce more insulin. In type 2 diabetes, where beta cells are functional but overworked, this approach can be effective. In LADA, it’s counterproductive.
Pushing already-damaged beta cells to work harder accelerates their destruction in two ways. First, the constant stimulation leads to exhaustion and increased cell death. Second, there’s evidence that forcing more insulin production increases the expression of the very proteins the immune system is targeting, essentially waving a flag that draws more autoimmune attack. In one study, 60% of autoantibody-positive patients treated with sulfonylureas progressed to needing insulin within just two years, compared to 15% of autoantibody-negative patients on the same medication.
Research comparing sulfonylureas to early insulin therapy in LADA paints a stark picture. After 30 months, patients on sulfonylureas showed worsening blood sugar control and a nearly 40% decline in beta cell function from their baseline. Patients started on insulin instead maintained their beta cell function over the same period. In one trial, six out of eight patients on insulin alone actually saw improvements in their autoimmune markers, with the antibodies that signal beta cell destruction becoming undetectable. Starting insulin earlier in LADA appears to give the remaining beta cells a chance to rest and may slow the autoimmune process itself.
Living With LADA
If you’ve been diagnosed with type 2 diabetes but find that your medications aren’t controlling your blood sugar well, you’re losing weight without trying, or you have a personal or family history of autoimmune conditions like thyroid disease or celiac disease, it’s worth asking about antibody testing. A simple blood draw can clarify whether autoimmune destruction is part of the picture.
Getting the right diagnosis changes your treatment path in a meaningful way. It means avoiding medications that could accelerate beta cell loss and starting insulin at the right time, potentially preserving whatever insulin production you still have for longer. People with LADA manage their condition much like people with type 1 diabetes once they become insulin dependent: monitoring blood sugar, adjusting insulin doses, and paying attention to how food and activity affect their levels. The earlier you know what you’re dealing with, the better positioned you are to protect the beta cells you still have.